What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in…
What is Black Diamond Therapeutics, Inc.'s P/E and P/B ratio?
Black Diamond Therapeutics, Inc. has a P/E ratio of -2.8 and a P/B ratio of 1.24.
What is Black Diamond Therapeutics, Inc.'s debt-to-equity ratio?
Black Diamond Therapeutics, Inc. has a debt-to-equity ratio of 0.18.
How much does Black Diamond Therapeutics, Inc. owe compared with what it owns?
Black Diamond Therapeutics, Inc. owes $0.23 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Black Diamond Therapeutics, Inc.'s Positivity rank?
Black Diamond Therapeutics, Inc. is ranked #2,808 of 6,774 companies globally and #1,016 of 4,000 in United States on PositoAI, with a Positivity Score of 21,122.
Does Black Diamond Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Black Diamond Therapeutics, Inc..
Where can I read the latest news about Black Diamond Therapeutics, Inc.?
Recent headlines about Black Diamond Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Black Diamond Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Black Diamond Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.